Head of Drug Product MSAT Synthetics Platform
About the job
- Ph.D. or advanced degree in Pharmaceutical Sciences, Chemical Engineering, Chemistry, or a related field.
- Approximately 12 or more years of experience in the pharmaceutical industry, including senior leadership roles.
- Strong expertise in drug product development and manufacturing, including formulation, process development, scale-up, and validation.
- Deep knowledge of chemistry, manufacturing, and controls, good manufacturing practices, and global regulatory frameworks including ICH, FDA, and EMA.
- Proven experience with regulatory submissions and health authority interactions.
- Demonstrated ability to lead in a complex, global matrix organization.
- Lead, develop, and inspire a multidisciplinary Drug Product organization, fostering a high-performance, accountable, and collaborative culture.
- Establish and inspire a cross-site skill area network.
- Define the organizational model, capabilities, and ways of working required to deliver current and future portfolio needs.
- Provide technical leadership and mentorship to a diverse team with expertise in pharmaceutical formulation, process development, scale-up, and manufacturing support for synthetic drug products.
- Build and sustain strong leadership within the team, including succession planning and talent pipeline development.
- Contribute to the Synthetics Platform's effectiveness through active participation in Global MSAT, M&S GenMed, R&D CMC Development, Industrial Product Teams, and Drug Product Manufacturing Site governance forums.
- Define and execute the global Drug Product strategy for the synthetic product portfolio across launch and commercialization.
- Ensure robust, compliant, and efficient formulation and process development for oral solid dosage, semi-solids, liquids, and emerging formats.
- Drive platformization, standardization, and harmonization of Drug Product processes, formulations, and control strategies across the network.
- Lead lifecycle management, including post-approval changes, cost optimization, and process improvements.
- Ensure all Drug Product activities meet global regulatory expectations, including ICH, FDA, and EMA requirements.
- Provide end-to-end oversight of technology transfer, validation, and commercial manufacturing support for Drug Product processes.
- Ensure robust control strategies for critical quality attributes and process performance across the lifecycle.
- Lead complex troubleshooting, root cause investigations, and technical decision-making at product and network level.
- Drive continuous improvement in yield, reliability, compliance, and cost efficiency.
- Ensure strong integration with MSAT transversal teams, sites, and contract manufacturing organizations.
- Drive innovation in formulation science, process technologies, and manufacturing approaches, including continuous manufacturing, advanced characterization, and process analytical technology.
- Lead implementation of digital solutions for Drug Product development and manufacturing, including data-driven process monitoring, digital twins and modeling where applicable, and data integrity and analytics frameworks.
- Build external partnerships with academia and industry to strengthen scientific and technological leadership.
- Define and articulate a clear vision and ambition for Drug Product within the Synthetics Platform.
- Influence enterprise-level decisions as a trusted technical and business leader.
- Contribute to the broader MSAT and M&S strategy, including operating model evolution.
- Drive cross-functional alignment across R&D, Manufacturing, Quality, Regulatory, and Digital.
- Champion change management and transformation in a complex, global environment.
- Experience managing broad and complex small-molecule Drug Product portfolios.
- Strong track record in commercial manufacturing support and lifecycle management.
- Experience in digital transformation and advanced manufacturing technologies.
- Demonstrated success in leading cross-functional CMC and lifecycle management teams.
- Exposure to continuous manufacturing, process analytical technology, and data science applications.
- Strong external network within the pharmaceutical and scientific community.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.
Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...
Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)